Angiotensin 12 (1-9) Mechanisms, Clinical Value, and Researc

Angiotensin 1/2 (1-9): Mechanisms, Clinical Value, and Research Perspectives in Cardiovascular and Renal Therapeutics
Introduction [Related: exendin 4 antibody]
Angiotensin 1/2 (1-9) is a bioactive nonapeptide derived from the enzymatic cleavage of angiotensin I by angiotensin-converting enzyme 2 (ACE2). As a member of the renin-angiotensin system (RAS), Angiotensin (1-9) has garnered increasing attention for its modulatory effects on cardiovascular and renal physiology, distinct from the classical angiotensin II (Ang II) pathway. Unlike Ang II, which is primarily associated with vasoconstriction, sodium retention, and pro-fibrotic actions, Angiotensin (1-9) is emerging as a peptide with vasodilatory, anti-fibrotic, and cardioprotective properties (Ocaranza & Jalil, 2012, Hypertension). The mechanism of action of Angiotensin (1-9) involves its interaction with angiotensin type 2 receptors (AT2R), leading to downstream effects that counterbalance the deleterious actions of Ang II mediated through angiotensin type 1 receptors (AT1R). This paper provides a comprehensive overview of Angiotensin (1-9), focusing on its clinical value, challenges addressed in current therapeutics, supporting research evidence, experimental data, usage guidelines, and future research directions. [Related: molecular nmn]
Clinical Value and Applications [Related: 740y-p]
The clinical value of Angiotensin (1-9) lies in its potential to serve as a therapeutic agent for cardiovascular and renal diseases, including hypertension, heart failure, myocardial infarction, and chronic kidney disease. The peptide's ability to modulate the RAS axis offers a novel approach to disease management, particularly in conditions where excessive Ang II activity contributes to pathogenesis. Preclinical studies have demonstrated that Angiotensin (1-9) exerts anti-hypertrophic, anti-fibrotic, and anti-inflammatory effects, which are beneficial in attenuating cardiac remodeling post-myocardial infarction (Ocaranza et al., 2010, Hypertension). Additionally, Angiotensin (1-9) has shown promise in improving endothelial function and reducing oxidative stress, further supporting its role in cardiovascular protection (Ferreira et al., 2010, Peptides).
In renal pathologies, Angiotensin (1-9) has been implicated in reducing glomerular injury and proteinuria, suggesting a protective effect against the progression of chronic kidney disease (CKD) (Santos et al., 2013, Circulation Research). The peptide's actions are mediated through AT2R activation, leading to vasodilation, natriuresis, and inhibition of cell proliferation and fibrosis. These properties position Angiotensin (1-9) as a potential adjunct or alternative to current RAS inhibitors, such as ACE inhibitors and angiotensin receptor blockers (ARBs), particularly in patients with resistance or intolerance to these therapies.
Key Challenges and Pain Points Addressed
Current RAS-targeted therapies, including ACE inhibitors and ARBs, have significantly improved outcomes in cardiovascular and renal diseases. However, several challenges persist, including incomplete RAS blockade, adverse effects (e.g., cough, angioedema), and the phenomenon of "aldosterone escape" or "angiotensin II escape," where Ang II levels rebound despite therapy (Remuzzi et al., 2005, Kidney International). Furthermore, these agents do not fully address the imbalance between the deleterious and protective arms of the RAS, particularly the underutilization of the ACE2/Angiotensin (1-9)/AT2R axis.
Angiotensin (1-9) addresses these pain points by providing a mechanism to enhance the protective arm of the RAS without the adverse effects associated with ACE inhibition. Its ability to activate AT2R and counteract the effects of Ang II offers a complementary approach to existing therapies. Moreover, Angiotensin (1-9) may be beneficial in patients with ACE inhibitor or ARB intolerance, and in those with persistent disease progression despite optimal RAS blockade. The peptide's anti-fibrotic and anti-inflammatory properties also address the limitations of current therapies in preventing tissue remodeling and fibrosis, which are critical determinants of long-term outcomes in cardiovascular and renal diseases.
Literature Review
A growing body of evidence supports the therapeutic potential of Angiotensin (1-9) in cardiovascular and renal diseases:
1. **Ocaranza, M. P., & Jalil, J. E. (2012). "Protective role of the ACE2/Ang-(1-9) axis in cardiovascular remodeling." Hypertension, 59(4), 804-810.** This review highlights the role of the ACE2/Ang-(1-9) axis in counteracting cardiovascular remodeling, emphasizing the anti-hypertrophic and anti-fibrotic effects of Angiotensin (1-9).
2. **Ocaranza, M. P., et al. (2010). "Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro." Hypertension, 56(6), 1122-1132.** This experimental study demonstrates that Angiotensin (1-9) administration attenuates cardiac hypertrophy and fibrosis in animal models, supporting its cardioprotective effects.
3. **Ferreira, A. J., et al. (2010). "Angiotensin-(1-9) and angiotensin-(1-7): peptides with opposing actions on vascular function." Peptides, 31(5), 939-943.** The authors compare the vascular effects of Angiotensin (1-9) and Angiotensin (1-7), showing that Angiotensin (1-9) induces vasodilation via AT2R activation.
4. **Santos, R. A. S., et al. (2013). "The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)." Circulation Research, 113(9), 1236-1248.** This review discusses the broader context of the ACE2/Angiotensin (1-9)/Angiotensin (1-7) axis, highlighting the renal protective effects of Angiotensin (1-9).
5. **Remuzzi, G., et al. (2005). "Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors in the treatment of proteinuria." Kidney International, 68(2), 518-528.** The paper outlines the limitations of current RAS inhibitors and the need for novel agents that target alternative RAS pathways, such as Angiotensin (1-9).
6. **Benter, I. F., et al. (2008). "Angiotensin-(1-9) prevents cardiac hypertrophy induced by angiotensin II in rats." American Journal of Physiology-Heart and Circulatory Physiology, 295(2), H762-H768.** This study provides evidence that Angiotensin (1-9) administration prevents Ang II-induced cardiac hypertrophy, further supporting its therapeutic potential.
7. **Karnik, S. S., et al. (2015). "Structure and function of the AT2 receptor: insights from molecular modeling and mutagenesis studies." Current Opinion in Pharmacology, 21, 1-7.** This review provides insights into the structure and function of the AT2R, the primary receptor mediating Angiotensin (1-9) effects.
Experimental Data and Results
Preclinical studies have elucidated the biological effects of Angiotensin (1-9) in various disease models. In a seminal study by Ocaranza et al. (2010), chronic administration of Angiotensin (1-9) in spontaneously hypertensive rats resulted in significant reductions in left ventricular hypertrophy and interstitial fibrosis, as assessed by echocardiography and histological analysis. These effects were associated with decreased expression of pro-fibrotic markers (e.g., TGF-β1, collagen I) and increased expression of anti-fibrotic genes. Importantly, the beneficial effects of Angiotensin (1-9) were abrogated by AT2R antagonism, confirming the receptor-mediated mechanism.
Similarly, Benter et al. (2008) demonstrated that Angiotensin (1-9) administration prevented Ang II-induced cardiac hypertrophy in rats, with reductions in heart weight-to-body weight ratio and cardiomyocyte cross-sectional area. The peptide also improved cardiac function, as evidenced by enhanced ejection fraction and reduced left ventricular end-diastolic pressure.
In renal disease models, Angiotensin (1-9) has been shown to reduce proteinuria, glomerulosclerosis, and renal fibrosis. Santos et al. (2013) reported that Angiotensin (1-9) treatment attenuated renal injury in a model of 5/6 nephrectomy, with improvements in glomerular filtration rate and reductions in inflammatory and fibrotic markers.
Collectively, these experimental data support the therapeutic potential of Angiotensin (1-9) in modulating cardiovascular and renal remodeling, Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 26 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11581775